Related references
Note: Only part of the references are listed.Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Konstanze Doehner et al.
BLOOD (2020)
FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation
Hong Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
The importance of FLT3 mutational analysis in acute myeloid leukemia
Mrinal M. Patnaik
LEUKEMIA & LYMPHOMA (2018)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study
Akira Shimada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
Masahiro Sakaguchi et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Acute Myeloid Leukemia, Version 3.2017
Margaret R. O'Donnell et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531
Erin M. Guest et al.
BLOOD (2017)
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2016)
Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia
Noraini Mat Yunus et al.
Asian Pacific Journal of Cancer Prevention (2015)
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
David C. Linch et al.
BLOOD (2014)
Allelic ratio: a marker of clonal dominance
Soheil Meshinchi
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
A critical review of which children with acute myeloid leukaemia need stem cell procedures
Henrik Hasle
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort
Magdalena Koszarska et al.
LEUKEMIA & LYMPHOMA (2014)
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML
D. L. Stirewalt et al.
BLOOD CANCER JOURNAL (2014)
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Marta Pratcorona et al.
BLOOD (2013)
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia
Anna Staffas et al.
BLOOD (2011)
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
Phoenix A. Ho et al.
BLOOD (2010)
Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia:: A study of the Japanese Childhood AML Cooperative Study Group
Akira Shimada et al.
PEDIATRIC BLOOD & CANCER (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Clinical implications of FLT3 mutations in pediatric AML
Soheil Meshinchi et al.
BLOOD (2006)
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia:: prognostic significance and relation to cellular drug resistance
CM Zwaan et al.
BLOOD (2003)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
KF Tse et al.
LEUKEMIA (2001)
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2001)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Y Yamamoto et al.
BLOOD (2001)
Share Paper
